![]() Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| ![]() Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. | ||
Founding Date | Founding Date 2006 | Founding Date 2000 | Founding Date 1989 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations San Diego, US HQ San Diego, US | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations Carlsbad, US HQ |
Employees | Employees 31019% decrease | Employees 999 | Employees 92716% increase |
Valuation ($) | Valuation ($) 1.5 m | Valuation ($) 648.3 m | Valuation ($) 6.3 b |
Financial | |||
Revenue (est.) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) €53.8m (FY, 2023) | Revenue (est.) $787.6m (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods €64.3m (FY, 2023) | Cost of goods $9.1m (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit (€2.6m) (FY, 2023) | Gross profit $778.5m (FY, 2023) |
Net income | Net income ($577.8m) (FY, 2022) | Net income (€260.2m) (FY, 2023) | Net income ($366.3m) (FY, 2023) |
Operating ⚠ | |||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 3 (May, 2020) | Phase I Trials Products 1 (FY, 2023) |
Funding | |||
Total funding raised | Total funding raised $ 42.6m | Total funding raised $ 1.1b | Total funding raised N/A |
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View companyIonis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
View company